Receive our newsletter – data, insights and analysis delivered to you
  1. Clinical Trials Analysis
September 21, 2021updated 23 Sep 2021 3:59pm

Lymphoma accounts for 9.8% share of global Oncology clinical trial activity in 2020

Lymphoma accounted for a 9.8% share of the global clinical trials within the Oncology therapy area in 2020, registering a decrease of 0.3% when compared with the last ten-year average of 10.1% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored trials outnumber industry sponsored trials for Lymphoma

Industry sponsored trials held a 43.0% share of all the clinical trials for Lymphoma indication in 2020, registering an increase of 5.2% when compared with the ten-year average of 37.8%. Non-industry sponsored trials accounted for a 57.0% share in 2020, marking a decrease of 5.2% over the ten-year average of 62.2%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Lymphoma trials

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Asia-Pacific was the top region for industry sponsored Lymphoma trials, accounting for a 66.2% share in 2020, when compared with the five-year average of 53.4% and ten-year average of 42.3%.

North America was at the second position with a 36.9% share in 2020, over the five-year average of 59.1% and ten-year average of 65.0%, followed by Europe with a 24.7% share in 2020, as against five-year and ten-year averages of 37.4% and 41.1% respectively.

Middle East and Africa stood fourth with a 3.0% share in 2020, compared with the five-year average of 7.6% and ten-year average of 8.2%, followed by South and Central America with a 1.5% share in 2020, over five-year and ten-year averages of 4.9% and 5.8% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for industry sponsored Lymphoma trials, accounting for a 44.9% share in 2020, as against the five-year average of 27.0% and ten-year average of 16.2%.

The US held a 36.9% share in 2020, over the five-year average of 58.1% and ten-year average of 63.0%, followed by Spain with a 12.6% share in 2020, compared with the five-year and ten-year averages of 21.0% and 20.3% respectively.

The UK held a 10.6% share in 2020, as against the five-year average of 17.9% and ten-year average of 19.5%.

Japan held a 10.1% share in 2020, over the five-year and ten-year averages of 12.4% and 12.1% respectively.

Top regions of non-industry sponsored Lymphoma trials

Asia-Pacific was the top region for non-industry sponsored Lymphoma trials, accounting for a 56.2% share in 2020 when compared with the five-year average of 39.3% and ten-year average of 31.7%.

North America was at the second position with a 33.8% share in 2020, over the five-year and ten-year averages of 43.7% and 47.3% respectively, followed by Europe with a 9.0% share in 2020, as against the five-year average of 16.5% and ten-year average of 21.5%.

Middle East and Africa stood at the fourth position with a 1.4% share in 2020, compared with the five-year average of 3.2% and ten-year average of 2.2%, followed by South and Central America with a 0.3% share in 2020, over the five-year and ten-year averages of 0.4% and 0.5% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Lymphoma trials, accounting for a 47.6% share in 2020, as against the five-year average of 25.4% and ten-year average of 16.6%.

The US held a 33.1% share in 2020, over the five-year average of 42.3% and ten-year average of 46.2%, followed by France with a 3.1% share, compared with the five-year and ten-year averages of 3.9% and 4.8% respectively.

Japan held a 3.1% share in 2020, as against the five-year average of 5.7% and ten-year average of 7.6%.

South Korea held a 2.4% share in 2020, over the five-year average of 3.5% and ten-year average of 3.2%.

Phase I trials lead industry sponsored clinical trials for Lymphoma in 2020

Phase I trials held a 50.0% share of industry sponsored clinical trials for Lymphoma in 2020, over the five-year average of 43.4% and ten-year average of 44.3%.

Phase II trials held a 38.1% share in 2020, as against the five-year average of 41.3% and ten-year average of 38.6%. Phase III trials held an 8.8% share in 2020, compared with the five-year and ten-year averages of 10.5% and 11.9% respectively.

Phase IV trials held a 3.1% share in 2020, over the five-year average of 4.8% and ten-year average of 5.2%.

Phase II trials lead non-industry sponsored clinical trials for Lymphoma in 2020

Phase II trials held a 56.7% share of non-industry sponsored clinical trials for Lymphoma in 2020, over the five-year average of 61.3% and ten-year average of 64.8%.

Phase I trials held a 32.3% share in 2020, as against the five-year average of 23.4% and ten-year average of 21.5%. Phase IV trials held a 6.3% share, compared with the five-year and ten-year averages of 8.6% and 7.3% respectively.

Phase III trials held a 4.7% share in 2020, over the five-year average of 6.8% and ten-year average of 6.4%.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU